, Volume 27, Issue 6, pp 1309–1318 | Cite as

Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia–reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway

  • Jing-Si Duan
  • Shuo Chen
  • Xiao-Qing Sun
  • Juan DuEmail author
  • Zhi-Wu ChenEmail author
Original Article


SB-706375 is a selective receptor antagonist of human urotensin-II (hU-II), which can block the aorta contraction induced by hU-II in rats. The effect of SB-706375 on myocardial ischaemia–reperfusion (I/R) injury is unclear. The major objective of this study was to investigate whether SB-706375 has a protective effect on myocardial I/R injury in rats and explore its possible mechanisms. Isolated hearts of Adult Sprague–Dawley were perfused in a Langendorff apparatus, and haemodynamic parameters, lactate dehydrogenase (LDH), creatine phosphokinase-MB (CK-MB), cardiac troponin I (cTnI), RhoA, and the protein expressions of U-II receptor (UTR), receptor-interacting protein 3 (RIP3), Rho-associated coiled-coil-containing protein kinase 1 (ROCK1) and Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) were assessed. We found that SB-706375 (1 × 10−6 and 1 × 10−5 mol/L) significantly inhibited the changes of haemodynamic parameters and reduced LDH and CK-MB activities and also cTnI level in the coronary effluents in the heart subjected to myocardial I/R injury. Further experiments studies showed that SB-706375 obviously prevented myocardial I/R increased RhoA activity and UTR, RIP3, ROCK1, and ROCK2 protein expressions. ROCK inhibition abolished the improving effect of SB-706375 on myocardial I/R-induced haemodynamic change in the isolated perfused rat heart. These findings suggested that SB-706375 provides cardio-protection against I/R injury in isolated rats by blocking UTR-RhoA/ROCK-RIP3 pathway.


SB-706375 Myocardial ischaemia reperfusion injury UTR-RhoA/ROCK-RIP3 pathway 



This work was financially supported by the National Natural Science Foundation of China (Project # 81374002, to Z.-W. Chen).


  1. Ammirati E, Dobrev D (2018) Conventional troponin-I versus high-sensitivity troponin-T: performance and incremental prognostic value in non-ST-elevation acute myocardial infarction patients with negative CK-MB based on a real-world multicenter cohort. Int J Cardiol Heart Vasc 20:38–39. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bao W et al (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548–558. CrossRefPubMedGoogle Scholar
  3. Cadete VJ, Sawicka J, Polewicz D, Doroszko A, Wozniak M, Sawicki G (2010) Effect of the Rho kinase inhibitor Y-27632 on the proteome of hearts with ischemia-reperfusion injury. Proteomics 10:4377–4385. CrossRefPubMedGoogle Scholar
  4. Cantin C et al (2019) Effect of early normotension with olmesartan on rho-kinase activity in hypertensive patients. Curr Vasc Pharmacol. CrossRefPubMedGoogle Scholar
  5. Chen ZW, Yang Q, Huang Y, Fan L, Li XW, He GW (2010) Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery. Vasc Pharmacol 52:70–76. CrossRefGoogle Scholar
  6. Ding H, Gao S, Wang L, Wei Y, Zhang M (2019) Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis. J Stroke Cerebrovasc Dis 28:149–155. CrossRefPubMedGoogle Scholar
  7. Dominguez-Rodriguez A, Diaz I, Rodriguez-Moyano M, Calderon-Sanchez E, Rosado JA, Ordonez A, Smani T (2012) Urotensin-II signaling mechanism in rat coronary artery: role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arterioscl Thromb Vasc Biol 32:1325–1332. CrossRefPubMedGoogle Scholar
  8. Douglas SA et al (2005) Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145:620–635. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Forty EJ, Ashton N (2013) The urotensin system is up-regulated in the pre-hypertensive spontaneously hypertensive rat. PLoS One 8:e83317. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Hamid SA, Bower HS, Baxter GF (2007) Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292:H2598–H2606. CrossRefPubMedGoogle Scholar
  11. He K et al (2014) ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. Am J Physiol Heart Circ Physiol 307:H1764–H1776. CrossRefPubMedGoogle Scholar
  12. Jani PP, Narayan H, Ng LL (2013) The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure. Peptides 40:72–76. CrossRefPubMedGoogle Scholar
  13. Jeddi S, Khalifi S, Ghanbari M, Bageripour F, Ghasemi A (2016) Effects of nitrate intake on myocardial ischemia-reperfusion injury in diabetic rats. Arq Bras Cardiol 107:339–347. CrossRefPubMedPubMedCentralGoogle Scholar
  14. Kamijo H et al (2011) Impaired vascular remodeling in the yolk sac of embryos deficient in ROCK-I and ROCK-II. Genes Cells 16:1012–1021. CrossRefPubMedGoogle Scholar
  15. Kilic S et al (2014) The effect of thrombus aspiration during primary percutaneous coronary intervention on clinical outcome in daily clinical practice. Thromb Haemost 111:165–171. CrossRefPubMedGoogle Scholar
  16. Lee JH, Park BK, Oh KS, Yi KY, Lim CJ, Seo HW, Lee BH (2016) A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. Int Immunopharmacol 40:196–202. CrossRefPubMedGoogle Scholar
  17. Luo SY, Chen S, Qin YD, Chen ZW (2016) Urotensin-receptor antagonist SB-710411 protects rat heart against ischemia-reperfusion injury via RhoA/ROCK pathway. PloS One 11:6094. CrossRefGoogle Scholar
  18. Maryanoff BE, Kinney WA (2010) Urotensin-II receptor modulators as potential drugs. J Med Chem 53:2695–2708. CrossRefPubMedGoogle Scholar
  19. Moriwaki K, Chan FK (2013) RIP3: a molecular switch for necrosis and inflammation. Genes Dev 27:1640–1649. CrossRefPubMedPubMedCentralGoogle Scholar
  20. Mucha E, Hoefle C, Huckelhoven R, Berken A (2010) RIP3 and AtKinesin-13A—a novel interaction linking Rho proteins of plants to microtubules. Eur J Cell Biol 89:906–916. CrossRefPubMedGoogle Scholar
  21. Ocaranza MP, Fierro C, Jalil JE, Moya J, Gonzalez L, Molina C, Mancilla C (2018) Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling. Clin Sci (Lond) 132:1837–1853. CrossRefGoogle Scholar
  22. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77:5021–5024CrossRefGoogle Scholar
  23. Sahna E, Acet A, Ozer MK, Olmez E (2002) Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 33:234–238CrossRefGoogle Scholar
  24. Satoh K, Fukumoto Y, Shimokawa H (2011) Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 301:H287–H296. CrossRefPubMedGoogle Scholar
  25. Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62:341–354. CrossRefPubMedGoogle Scholar
  26. Wang K et al (2016) The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ 23:1394–1405. CrossRefPubMedPubMedCentralGoogle Scholar
  27. Yang Z et al (2018) Melatonin attenuates chronic pain related myocardial ischemic susceptibility through inhibiting RIP3-MLKL/CaMKII dependent necroptosis. J Mol Cell Cardiol 125:185–194. CrossRefPubMedGoogle Scholar
  28. You Z, Genest J Jr, Barrette PO, Hafiane A, Behm DJ, D’Orleans-Juste P, Schwertani AG (2012) Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. Arterioscl Thromb Vasc Biol 32:1809–1816. CrossRefPubMedGoogle Scholar
  29. Yu ZY et al (2014) RhoA/ROCK signaling and pleiotropic alpha1A-adrenergic receptor regulation of cardiac contractility. PloS One 9:e99024. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Zhang JY, Chen ZW, Yao H (2012) Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase—Akt pathway. Can J Physiol Pharmacol 90:637–645. CrossRefPubMedGoogle Scholar
  31. Zhang T et al (2016) CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med 22:175–182. CrossRefPubMedGoogle Scholar
  32. Zhang FW, Tong J, Yan YS, Chen QQ, Zhao XP (2018a) omega-3 polyunsaturated fatty acid postconditioning protects the isolated perfused rat heart from ischemia-reperfusion injury. Cardiorenal Med 8:173–182. CrossRefPubMedPubMedCentralGoogle Scholar
  33. Zhang X et al (2018b) Clinical significance of increased urotensin II levels in acute myocardial infarction. Discov Med 26:7–20PubMedGoogle Scholar
  34. Zhuang R et al (2018) Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease. Int J Mol Med 42:1341–1352. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacologyAnhui Medical UniversityHefeiChina
  2. 2.Department of PhysiologyAnhui Medical UniversityHefeiChina
  3. 3.Department of Cardiovascular SurgeryThe 1st Affiliated Hospital of Anhui Medical UniversityHefeiChina

Personalised recommendations